首页>投融资
ONWARD
IPO后其他轮次
ONWARD Inc (previously known as GTX Medical) is a MedTech company focused on the development and commercialization of innovative therapies to accelerate and augment functional recovery of people with spinal cord injury and to improve their quality of life.In June 2022, ONWARD Inc received a grant from the European Commission of EUR 3.6 million to support the enhancement of an innovative brain-computer interface technology for restoring mobility and upper-limb function in people with spinal cord injury
基本信息
-
公司全称ONWARD Inc
-
类型植入式神经刺激器开发商
-
产业领域器械/设备、试剂/耗材
-
公司人数15~50人
-
地址High Tech Campus 32 EINDHOVEN NOORD-BRABANT 5656AE; NL;
-
联系电话
-
邮箱
-
成立时间2014-01-01
投融资
-
2024-10-24IPO后其他轮次5400万美元未透露
-
2024-03-21IPO后其他轮次2000万欧元未透露
-
2022-06-16IPO后其他轮次120万欧元European Innovation Council
-
2021-10-21上市8700万欧元未透露
-
2021-04-22未公开3200万美元GimvInvest-NLINKEF CapitalOlympic InvestmentsWellington PartnersLife Sciences Partners
-
2019-03-19捐赠/众筹/授予未透露Eurostars
-
2016-04-19债权融资1000万欧元未透露
-
2016-04-19A轮2600万欧元Life Sciences PartnersGimvINKEF CapitalWellington Partners
-
2014-04-12捐赠/众筹/授予10万欧元未透露
- 加载更多
相关投融资企业
IPO后其他轮次
ONWARD Inc (previously known as GTX Medical) is a MedTech company focused on the development and commercialization of innovative therapies to accelerate and augment functional recovery of people with spinal cord injury and to improve their quality of life.In June 2022, ONWARD Inc received a grant from the European Commission of EUR 3.6 million to support the enhancement of an innovative brain-computer interface technology for restoring mobility and upper-limb function in people with spinal cord injury
未公开
ATANIS Biotech是一家生物技术公司的经营者,旨在简化和改善目前过敏诊断的护理标准。该公司提供了一种新颖的基于功能细胞的检测方法,简化了过敏的诊断,并可以预测治疗的治疗成功率,为客户提供了一种可靠的功能性过敏筛查工具。
收并购
Omixon是一家全球性的移植诊断公司,其使命是为组织相容性实验室提供创新技术,以改善移植结果。Omixon总部位于匈牙利布达佩斯,在美国、巴西和荷兰设有分支机构,为全球60多家实验室提供服务。2014年,Omixon率先成功推出基于ngs的HLA分型试剂盒和软件,将基于ngs的HLA基因分型产品Holotype HLA和HLA Twin软件推向市场。Omixon Twin提供最准确的高分辨率HLA基因分型,并在全球60多个实验室中使用。